Join
Live feed
·
PRReleasevia Quantisnow
Taysha Gene Therapies Inc. logo

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
TSHA· Taysha Gene Therapies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TSHA (Taysha Gene Therapies Inc.) and more on Quantisnow.